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Background: The primary objective of our study was to investigate the prevalence of off-label 
antidepressant drug use in insomnia. The secondary objective was to compare prescribing 
patterns between off-label antidepressants vs hypnotics approved by the US Food and Drug 
Administration for insomnia, with particular emphasis on socioeconomic characteristics of 
patients and physicians.
Methods: We undertook a secondary data analysis using the national longitudinal database from 
the 2006 National Ambulatory Medical Care Survey. Subjects were identified from outpatient 
visits in which at least one insomnia drug was prescribed. A series of weighted Chi-squared 
statistics was used to compare drug use for insomnia across various patient and physician 
characteristics. Multivariate logistic regression was conducted to identify factors associated 
with off-label antidepressant drug use.
Results: Among 901.95 million outpatient visits that took place in the US in 2006, an esti-
mated 30.43 million visits included at least one drug prescription for insomnia. Off-label 
antidepressants were prescribed significantly more frequently (45.1%) than nonbenzodiazepine 
z-hypnotics (43.2%) and benzodiazepines (11.7%). Insomnia prescribing patterns were signifi-
cantly influenced by physician specialty and physician office settings. Pediatricians (odds ratio 
[OR]: 65.892; 95% confidence interval [CI]: 5.536–810.564) and neurologists (OR: 4.784; 95% 
CI: 2.044–11.201) were more likely to prescribe off-label antidepressants than psychiatrists. 
  Self-paying patients were more likely to receive off-label antidepressants as treatment for 
insomnia than patients with private insurance (OR 2.594; 95% CI: 1.128–5.967).
Conclusion: Our findings indicate significant socioeconomic disparities in the use of off-label 
antidepressants. Future studies might explore interventional and educational strategies to ensure 
well informed clinical decisions that can withstand pharmaceutical marketing strategies and 
diagnostic uncertainties regarding the treatment of insomnia.
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Introduction
Insomnia, defined as difficulty initiating and maintaining sleep, is currently the most 
prevalent sleep disorder. Approximately 20% of adults examined in a general medical 
setting experience severe and persistent insomnia.1 According to the National Sleep 
Foundation’s 2008 “Sleep in America Poll”, as many as 65% of adults report one or 
more sleep difficulties at least several times per week, with 44% experiencing sleep 
difficulties on a nightly basis.2 The costs of insomnia, both direct and indirect, range 
from US$92.5 to US$107.5 billion annually.3 However, the market for insomnia drugs Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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is not saturated. There is a potential for increased drug sales 
and patient awareness of available treatments. Current pre-
scription medications approved by the US Food and Drug 
Administration (FDA) for insomnia include five benzodiaz-
epines (estazolam, flurazepam, quazepam, temazepam, and 
triazolam), three nonbenzodiazepine z-hypnotics (eszopi-
clone, zalepon, and zolpidem),4 and one selective melatonin 
receptor agonist (ramelteon).5 Despite the availability of 
these drugs, studies consistently show a rise in off-label 
prescriptions for antidepressants, antipsychotics, and anti-
convulsants in the treatment of insomnia.6,7 Antidepressants 
accounted for three of the most often prescribed hypnotics, 
which are trazodone, amitriptyline, and mirtazapine.8 In other 
reports, trazodone has contributed to approximately 20% of 
total insomnia drug sales in the market.9,10 However, there is 
growing concern that off-label use of antidepressants may 
also put patients at higher risk for medication errors, side 
effects, and unwanted drug reactions.
Off-label prescribing, also called “nonapproved” or 
“unapproved” use of a drug, is the practice of prescribing 
medication for purposes different from those indicated by the 
FDA. Off-label drug use contributes to approximately 21% 
of prescriptions written annually.11 The use of off-label drugs 
is not illegal and is regularly practiced across the country. 
The FDA does not regulate the practice of medicine, and 
this translates into freedom of off-label drug use by licensed 
practitioners.11,12 Numerous physicians believe it is a privilege 
accorded to the medical practitioner based on their profes-
sional experience under certain circumstances. It has been 
argued that off-label prescription provides a flexible and 
experimental platform for fostering the discovery of a new 
drug indication.11 Yet, specialists warn that off-label use may 
be more risky due to lack of safety and efficacy data.3,7,11
Amongst off-label drug uses, antidepressant use is one of 
the most common.11 Closely related to the issue of off-label 
antidepressant drug use for insomnia are sociodemographic 
characteristics of physicians and patients. Physicians may 
believe erroneously that off-label medications have demon-
strated sustained efficacy and are safer. Physicians, as well 
as patients, may also choose antidepressants over hypnotics 
because of cost and formulary considerations. This decision-
making process involves complicated socioeconomic 
issues and interactions between the patient and physician. 
These sociological influences were first considered by John 
Eisenberg, who identified a series of physician and patient 
characteristics likely to influence the allocation of a given 
prescription.13 Using Eisenberg’s findings as a theoretical 
framework, several insomnia researchers have examined 
prescribing patterns across variables such as physician 
specialty, patient gender, and patient ethnicity.14–16
The literature has shown that off-label drug use is wide-
spread but often not supported by strong evidence.11 To 
address this concern, the primary objective of our study was 
to investigate the prevalence of off-label antidepressant drug 
use in insomnia using a national representative database. The 
secondary objective was to compare prescribing patterns 
between off-label antidepressants vs FDA-approved hypnot-
ics for insomnia, with particular emphasis on market-driven 
patient and physician socioeconomic characteristics.
Methods
Data source
Data were extracted from the National Ambulatory Medical 
Care Survey (NAMCS). The NAMCS is a national prob-
ability sample survey conducted annually by the Division of 
Health Care Statistics, National Center for Health Statistics, 
within the Centers for Disease Control and Prevention. The 
NAMCS sample data are collected from nonfederal office-
based clinical practices. The basic sampling unit for the 
NAMCS is the physician–patient encounter or outpatient 
visit. For each selected visit, physicians complete an encoun-
ter form listing diagnoses, medication, and clinical services 
that they provided. All records contain patient demographic 
information, including age, gender, race, ethnicity, and 
source of payment. Details of the NAMCS sampling design 
are available to the public online.17 To enable extrapolation 
to national estimates, each visit record is assigned an infla-
tion factor called the patient visit weight, which is then used 
to predict the total number of office visits made in the US. 
All estimates from the NAMCS are related to the number 
of patient visits and are subject to sampling variability. An 
estimate is considered reliable if it has a relative sampling 
error #30% of the estimate, as per NCHS standards. Our 
study used the 2006 NAMCS data for its timeliness and avail-
ability while this project was funded. All data management 
and analyses described were performed using SAS software 
(SAS Institute, Cary, NC).
Data extraction and methods
All patient visits to an ambulatory physician office, where 
at least one frequently used insomnia drug was prescribed, 
were extracted and categorized into two groups, ie, FDA-
approved insomnia prescriptions, including benzodiazepine 
hypnotics (flurazepam, quazepam, triazolam, estazolam, 
temazepam), nonbenzodiazepine hypnotics (zolpidem, zale-
plon, eszopiclone), and a selective melatonin receptor agonist Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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(ramelteon), and frequently used off-label antidepressants for 
insomnia, including amitriptyline, nortriptyline, mirtazapine, 
doxepin, and trazodone. Up to eight medications can be 
recorded for each visit in the NAMCS database. Each drug 
code was assigned a unique “generic drug code” by Multum’s 
Lexicon Plus system, which was used to classify drug entries 
in the NAMCS. The structure of the Multum database allows 
multiple-ingredient drugs to be assigned a single generic drug 
code according to their generic components and therapeutic 
classifications. Patients who were diagnosed with depression 
(ICD-9-CM codes 296.20, 296.30, 300.40, 309.00, 309.10, 
and 311.00) were excluded from the off-label antidepressant 
group to avoid overestimation of off-label antidepressant use. 
Using Eisenberg’s sociological theory, we also identified sev-
eral physician and patient characteristics as variables for fur-
ther analysis, ie, patient age, gender, ethnicity, insurance type, 
physician’s specialty, office setting, and office ownership. 
The study proposal was approved by the Institutional Review 
Board of Nova Southeastern University.
Statistical analysis
Each record on the NAMCS data file represents one patient 
visit. In order to obtain national estimates, the sample weight 
adjustments and standard error corrections were incorporated 
in all descriptive and inferential statistical analyses. We first 
performed a series of descriptive analyses to estimate the 
national weighted frequency of each drug. Second, we 
explored bivariate analyses to compare selected predictive 
variables associated with insomnia prescribing patterns 
between off-label antidepressants and FDA-approved hyp-
notics using weight-adjusted Chi-squared analyses. Third, 
a weighted multivariate logistic regression with SAS PROC 
SURVEYLOGISTICS application was conducted to predict 
the maximum likelihood of off-label antidepressant use associ-
ated with patient and physician socioeconomic characteristics. 
Both standard sample design variables (CSTRATM and 
CPSUM) were included in the SAS PROC SURVEYFREQ 
program to adjust for the complex sampling design employed 
by NAMCS. A two-tailed statistic with a P-value less than 
0.05 was considered statistically significant.
Results
Prevalence and bivariate analyses
An estimated total of 901.95 million outpatient visits occurred 
in the US in 2006. There were 30.43 million visits (3.4%) 
at which at least one frequently used insomnia drug was 
prescribed. FDA-approved benzodiazepines were prescribed 
at 3.53 million of these visits (11.6%), whereas FDA-
approved nonbenzodiazepine z-hypnotics were prescribed at 
12.55 million visits (41.2%). Non-FDA-approved insomnia 
medications were prescribed at 13.73 million visits (45.1%). 
The weighted frequency of these drugs is presented in Table 1. 
The most frequently prescribed drug was zolpidem, which 
accounted for 32.8% of total prescriptions. This was followed 
by trazodone (17.9%), amitriptyline (14.5%), temaze-
pam (8.7%), eszopiclone (7.5%), mirtazapine (5.8%), 
Table 1 Prevalence of insomnia drugs prescribed at US outpatient visits in 2006
Insomnia drugs Generic equivalent code Weighted frequency Percentage (%)
FDA-approved benzodiazepine hypnotics
  Temazepam (restoril®) d00384 2,644,074 8.7%
  estazolam (Prosom®) d00915 108,135 0.4%
  Triazolam (Halcion®) d00397 535,258 1.8%
  Flurazepam (Dalmane®) d00238 249,686 0.8%
  Quazepam (Doral®) d00917 0 0%
FDA-approved nonbenzodiazepine z-hypnotics
  Zolpidem (Ambien®) d00910 9,996,496 32.8%
  Zaleplon (Sonata®) d04452 265,363 0.9%
  eszopiclone (Lunesta®) d05421 2,290,378 7.5%
Selective melatonin receptor agonist
  ramelteon (rozerem®) d05778 614,907 2.0%
non FDA-approved antidepressants
  Trazodone (Desyrel®) d00395 5,435,674 17.9%
  Amitriptyline (elavil®) d00146 4,413,467 14.5%
  Mirtazapine (remeron®) d04025 1,761,523 5.8%
  nortriptyline (Aventyl®) d00144 1,424,346 4.7%
  Doxepin (Sinequan®) d00217 695,369 2.3%
Total 30,434,676 100.0%
Note: insomnia drugs selected according to the national institutes of Health report4 and rozerem® prescribing information.5
Abbreviation: FDA, Food and Drug Administration.Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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nortriptyline (4.7%), doxepin (2.3%), ramelteon (2.0%), 
triazolam (1.8%), zaleplon (0.9%), flurazepam (0.8%), and 
estazolam (0.4%). Figure 1 illustrates the prevalence of 
FDA-approved hypnotic and off-label antidepressant use in 
the treatment of insomnia.
Table 2 outlines the results from weight-adjusted Chi-
squared analyses comparing the off-label antidepressant group 
and the FDA-approved hypnotic group based on selected 
patient and physician characteristics. The off-label antide-
pressant group had a significantly lower mean age than the 
FDA-approved group (55.8 years vs 58.2 years, P = 0.0186). 
In the off-label antidepressant group, female patients received 
more insomnia prescriptions than did men (68.2% vs 31.8%). 
Similar trends were observed in the FDA-approved hypnotic 
group (62.2% vs 37.8%). In both groups, white patients were 
more likely to receive insomnia drugs, followed by Hispan-
ics, blacks, and other races. The majority of visits at which 
insomnia medications were prescribed were paid for by private 
insurance, Medicare, and Medicaid. This trend was consistent 
in both groups, but a significant difference was detected in 
the distribution based on payment mode.
Off-label antidepressant prescribing patterns were signifi-
cantly influenced by physician specialty (P , 0.001) and phy-
sician office setting (P , 0.001). General practitioners/family 
physicians prescribed the most insomnia prescriptions 
(off-label antidepressant group 27.8%, FDA-approved 
group 24.7%), followed by internal medicine physicians 
(off-label antidepressant group 22.3%, FDA-approved group 
26.0%) and psychiatric specialists (off-label antidepressant 
group 16.8%, FDA-approved group 16.4%, see Table 2 and 
  Figure 2). The majority of insomnia prescriptions were issued 
by private solo/group practices (off-label antidepressant 
group 80.5%, FDA-approved group 92.3%). However, there 
was a statistically significant difference in the distribution of 
insomnia prescriptions between the off-label antidepressant 
group and FDA-approved hypnotic group. Clinics owned 
by physicians prescribed more insomnia prescriptions (off-
label antidepressant group 72.9%, FDA-approved group 
80.1%) than other types of physician office ownership, such 
as a Health Maintenance Organization, community health 
center, or academic health center. However, no statistically 
significant difference in physician office ownership was found 
between the two groups.
Multivariate analysis
Results of multivariate logistic regression presented as odds 
ratios (OR) and 95% Wald confidence intervals (CI) are 
shown in Table 3. The adjusted OR represents the increased 
Insomnia drugs 
Off-label antidepressants 
FDA-approved hypnotics 
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Figure 1 Prevalence of FDA-approved hypnotics and off-label antidepressants use in the treatment of insomnia. 
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Table 2 Socioeconomic characteristics of off-label antidepressant group and FDA-approved hypnotic group
Variable Weighted frequency (%) P-value*
Off-label antidepressant group FDA-approved hypnotic group
Patient age
  Mean (years) 55.775 58.155 0.0186*
Patient gender
  Female 9,274,657 (68.2) 10,423,770 (62.2) 0.2145
  Male 4,325,960 (31.8) 6,325,183 (37.8)
Patient race
  White, non-hispanic 10,286,943 (75.6) 12,557,410 (75.0) 0.4536
  Black, non-hispanic 1,281,507 (9.4) 1,435, 060 (8.6)
  Hispanic 1,324,715 (9.7) 2,058,405 (12.3)
  Asian 411,237 (3.0) 573,677 (3.4)
  Native Hawaiian, other Pacific Islander 21,672 (0.2) 35,529 (0.2)
  American indian/Alaska native 231,518 (1.7) 88,872 (0.5)
  Multiple races 43,025 (0.3) 0 (0.0)
Physician specialty
  general/family practice 3,779,358 (27.8) 4,139,900 (24.7) ,0.001*
  internal medicine 3,028,144 (22.3) 4,347,494 (26.0)
  Pediatrics 214,920 (1.6) 4,690 (0.0)
  general surgery 257,555 (1.9) 181,795 (1.1)
  Obstetrics and gynecology 302,143 (2.2) 225,152 (1.3)
  Orthopedic surgery 316,399 (2.3) 678,631 (4.1)
  cardiovascular diseases 456,555 (3.4) 602,225 (3.6)
  Dermatology 84,648 (0.6) 103,652 (0.6)
  Urology 152,834 (1.1) 149,935 (0.9)
  Psychiatry 2,287,602 (16.8) 2,746,794 (16.4)
  neurology 881,278 (6.5) 386,081 (2.3)
  Ophthalmology 96,370 (0.7) 0 (0.0)
  Otolaryngology 99,222 (0.7) 104,060 (0.6)
  Other specialties 1,452,388 (10.7) 2,556,955 (15.3)
  Oncology 191,201 (1.4) 521,589 (3.1)
Physician office setting
  Private solo/group practice 10,941,224 (80.5) 15,463,752 (92.3) ,0.001*
  Free standing clinic/urgent center 1,441,709 (10.6) 605,762 (3.6)
  community health center 391,458 (2.9) 233,423 (1.4)
  Mental health center 272,676 (2.0) 152,946 (0.9)
  nonfederal government clinic 28,734 (0.2) 0 (0.0)
  HMO or other prepaid practice 499,100 (3.7) 223,104 (1.3)
  Faculty practice plan 25,716 (0.2) 69,966 (0.4)
Physician office ownership
  Physician or physician group 9,920,331 (72.9) 13,411,483 (80.1) 0.5634
  HMO* 573,486 (4.2) 348,105 (2.1)
  community health center 370,576 (2.7) 228,249 (1.4)
  Medical/academic health center 539,177 (4.0) 378,685 (2.3)
  Other hospital 843,240 (6.2) 819,082 (4.9)
  Other health care corporation 1,071,752 (7.9) 1,270,305 (7.6)
  Other 282,055 (2.1) 211,025 (1.3)
  Blank 0 (0.0) 82,019 (0.5)
Type of payment
  Blank 396,496 (2.9) 216,360 (1.3) 0.0342*
  Private insurance 5,288,962 (38.9) 7,799,779 (46.6)
  Medicare 4,400,684 (32.4) 5,546,188 (33.1)
  Medicaid 2,096,614 (15.4) 1,851,407 (11.1)
  Worker’s compensation 18,240 (0.1) 197,141 (1.2)
  Selfpay 740,144 (5.4) 395,585 (2.4)
  no charge 171,981 (1.3) 28,168 (0.2)
  Other 209,478 (1.5) 229,839 (1.4)
  Unknown 278,018 (2.0) 484,486 (2.9)
Note: *Indicates that weight-adjusted Chi-squared statistic is significant.
Abbreviations: HMO, Health Maintenance Organization; FDA, Food and Drug Administration.Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
32
Lai et al
likelihood of prescribing off-label antidepressants compared 
with FDA-approved hypnotics based on each socioeconomic 
characteristic, using a reference group in each category.
There was no significantly increased likelihood of prescrib-
ing off-label antidepressants in relation to patient age, gender, 
and ethnicity. However, self-paying patients were more likely to 
receive off-label antidepressants for insomnia than patients with 
private insurance (OR: 2.594; 95% CI: 1.128–5.967). In con-
trast, certain physician characteristics significantly increased the 
likelihood of prescribing off-label antidepressants for treatment 
of insomnia. Physicians from most specialties did not show an 
increased likelihood of prescribing off-label antidepressants, 
except for pediatricians and neurologists. Pediatricians (OR: 
65.892; 95% CI: 5.536–810.564) and neurologists (OR: 4.784; 
95% CI: 2.044–11.201) were more likely than psychiatrists to 
prescribe off-label antidepressants. Physicians from freestand-
ing clinics or urgent centers were also more likely to prescribe 
off-label antidepressants than those from private solo/group 
practices (OR: 3.26; 95% CI: 1.2–8.9).
Discussion
Of 901.95 million outpatient visits in the US in 2006, at least 
one insomnia drug was prescribed at 30.43 million visits, 
representing approximately 3.4% of visits, as opposed to 
the estimated 20% of adults reported to experience severe 
and persistent insomnia.1 This discrepancy could be due to 
selective “underprescribing”, a phenomenon that has been 
detected in other chronic diseases.18,19 However, widespread 
use of over-the-counter antihistamines might be another rea-
son for this occurrence. According to the National Institutes 
of Health, alcohol and over-the-counter drugs remain some 
of the most popular selfcare treatments for insomnia.4,20
Off-label antidepressants were prescribed in 45.1% of the 
prescriptions examined. This is nearly four times the amount 
of FDA-approved benzodiazepine prescriptions issued. The 
high prevalent use of off-label antidepressants for insomnia 
has been reported in other studies.21,22 Wiegand postulated 
that physicians favor antidepressants over FDA-approved 
benzodiazepines due to uninformed perceptions of the 
safety and nonaddictive advantages of antidepressants over 
benzodiazepine receptor agonists.23 It is equally likely that 
comorbidity with depression and anxiety disorders result 
in increased use of off-label antidepressants for insomnia 
treatment.24 An estimated 40% of all patients with insomnia 
have a coexisting psychiatric condition,25 and differences 
between insomnia and depressive symptoms can be ambigu-
ous.26 Although the diagnosis of depression was used as an 
exclusion criterion in our study, the influence of subclinical 
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Table 3 Likelihood of prescribing off-label antidepressants in the treatment of insomnia
Variable Adjusted odds ratio 95% Wald confidence interval
Patient age (years)
 , 15 0.870 0.153–4.932
  15–24 1.853 0.730–4.704
  25–44 0.827 0.425–1.609
  45–64 1.035 0.567–1.888
  65–74 1.019 0.532–1.951
  Above 75 years (reference) – –
Patient gender
  Female 1.219 0.850–1.750
  Male (reference) – –
Patient race
    White, non-hispanic (reference) – –
  Black, non-hispanic 0.816 0.351–1.896
  Hispanic 0.706 0.372–1.338
  Asian 0.634 0.246–1.629
    Native Hawaiian, other Pacific Islander 0.260 0.015–4.385
  American indian/Alaska native 2.176 0.232–20.424
Physician specialty
  general/family practice 1.811 0.867–3.783
  internal medicine 1.122 0.477–2.638
  Pediatrics 65.892 5.536–810.564*
  general surgery 3.136 0.817–12.030
  Obstetrics and gynecology 2.656 0.770–9.164
  Orthopedic surgery 1.406 0.398–4.968
  cardiovascular diseases 1.428 0.572–3.564
  Dermatology 1.328 0.243–7.258
  Urology 1.552 0.458–5.261
  Psychiatry (reference) – –
  neurology 4.784 2.044–11.201*
  Otolaryngology 2.015 0.611–6.649
  Other specialties 1.088 0.460–2.578
  Oncology 0.564 0.232–1.368
Physician office setting
    Private solo/group practice (reference) – –
  Free standing clinic/urgent center 3.255 1.186–8.938*
  community health center 2.970 0.543–16.254
  Mental health center 2.880 0.987–8.402
    HMO* or other prepaid practice 4.000 0.696–22.994
  Faculty practice plan 0.450 0.029–7.013
Physician office ownership
    Physician or physician group (reference) – –
  HMO 2.217 0.501–9.811
  community health center 1.222 0.183–8.137
    Medical/academic health center 2.372 0.756–7.445
  Other hospital 2.435 0.633–9.359
  Other health care corporation 2.298 0.948–5.570
  Other 1.603 0.422–6.090
Type of payment
  Private insurance (reference) – –
  Medicare 1.433 0.858–2.394
  Medicaid 1.617 0.888–2.947
  Worker’s compensation 0.230 0.024–2.175
  Selfpay 2.594 1.128–5.967*
  no charge 6.630 0.724–60.713
  Other 1.728 0.292–10.229
  Unknown 0.745 0.234–2.374
Note: *Indicates adjusted odds ratio with 95% confidence interval is significant.
Abbreviation: HMO, Health Maintenance Organization.Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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depression in the prescribing of off-label antidepressants 
cannot be ruled out. Even though prescribing antidepressants 
in the context of concurrent depression and insomnia is desir-
able, its use in the treatment of insomnia alone is unclear and 
arguably weak.6,23,27 Several randomized controlled trials have 
investigated the efficacy of antidepressants for insomnia,28–31 
but only a few studies have directly compared its efficacy 
with that of the benzodiazepine receptor agonists.32,33 No 
comparison with z-hypnotics has been conducted to date.
The high prevalence of off-label antidepressant use for 
treatment of insomnia may also be attributed to its lower cost, 
given that generic preparations are widely available. However, 
drug pricing does not fully explain our findings. A recent 
report cites the economically accessible trazodone as the most 
frequently prescribed insomnia medication.34 Our results show 
that zolpidem accounted for more prescriptions than did tra-
zodone, which is consistent with a report by Roy and Smith.35 
This finding may be explained by the distributor’s aggressive 
marketing efforts, such as direct-to-consumer advertising 
(DTCA). DTCA spending for zolpidem (Ambien®) was 
US$11.1 million in 2000 and zolpidem was ranked as the 
48th highest DTCA expenditure drug.36 A subsequent study by 
Donohue et al showed that this figure increased to US$88 mil-
lion in 2005, when zolpidem ranked the 14th highest DTCA 
expenditure drug.37 This amount has increased eight times 
within 5 years and DTCA is likely to have helped to secure 
its widespread usage, despite its reported side effects such 
as night-time eating, sleepwalking, daytime dizziness, and 
drowsiness.38,39 The impact of DTCA is explained by a survey 
in which 25%–33% of consumers talked to their physicians 
about the advertised drug they had seen, and 12%–25% of 
them asked to be prescribed the drug.40
It is surprising that there is high consistency in terms of 
the percentage of patients prescribed off-label antidepressants 
and FDA-approved hypnotics. This suggests that, despite the 
availability of FDA-approved hypnotics and their proven effi-
cacy, approximately half of all physicians are still prescribing 
off-label antidepressants for insomnia. Using logistic regres-
sion analysis, we identified pediatricians and neurologists 
as being more likely to prescribe off-label antidepressants 
than psychiatrists. The practice of prescribing hypnotics for 
pediatric insomnia is common among special needs children, 
particularly those with a depressive disorder. Thus, off-label 
antidepressants may be a complementary choice for the treat-
ment of insomnia in this population. In addition, concerns 
over the misuse of benzodiazepines and z-hypnotics in the 
pediatric population may increase the likelihood of pedia-
tricians prescribing off-label antidepressants. Increased use 
of off-label antidepressants may be attributed to concurrent 
neurological symptoms reported by patients, such as neuro-
pathic pain, that lead to difficulty sleeping.
Our study also found that physicians practicing at free-
standing clinics or urgent centers were 3.26 times more 
likely to prescribe an off-label antidepressant for treatment 
of insomnia than those practicing at private solo/group prac-
tices. There are many freestanding clinics (ie, not associated 
with a medical institution) that offer off-label treatment 
for various health conditions. These treatments are usually 
provided based upon cash payment, which is consistent with 
our study finding that self-paying patients were 2.59 times 
more likely to obtain an off-label antidepressant than those 
with private insurance.
Nevertheless, our study has several limitations. First, we 
showed that neurologists prescribed 4.8 times more off-label 
antidepressants than psychiatrists for treatment of insomnia. 
This finding may be confounded by other off-label antide-
pressant use, eg, for neuropathic pain, migraine prophylaxis, 
tension headache, fibromyalgia, and other indications. The 
presence of these concurrent complaints may increase the 
likelihood of physicians prescribing off-label antidepressants 
for treatment of insomnia.41 On the other hand, the addition 
of these diagnoses to the exclusion criteria for the off-label 
antidepressant group may underestimate the likelihood of 
prescribing off-label antidepressants for insomnia because of 
the coexistence of these symptoms with insomnia. However, 
there is also the possibility of overestimating the study effect 
due to use of ICD-9 codes for the exclusion of patients with 
depression from the off-label antidepressant group. The 
tendency to underdiagnose depression may be attributed to 
ICD coding and, therefore, many patients without an ICD-9 
code for depression were prescribed an antidepressant and 
included in the analysis.
Second, we used drug prescriptions for insomnia without 
an ICD-9 code because inclusion criteria may erroneously 
include patients without insomnia, as discussed earlier. 
Insomnia is frequently perceived as a symptom rather than 
a disorder, and ambiguity between insomnia and other 
psychiatric disorders render the use of the ICD-9 code inad-
equate. It is not uncommon for sedative antidepressants to 
be used in patients with depression and/or anxiety because 
of concurrent sleep difficulty. Additionally, our study did 
not take into account important reimbursement policies and 
institutional formularies that place restrictions on physicians’ 
prescribing behaviors. Due to the limitations of the NAMCS 
database, our results did not provide qualitative information 
on the physician–patient relationship which could be used Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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to formulate a physician education program in the future. 
We also did not take into consideration the effect of marital 
status in our analysis of demographic-based difference in 
prescribing patterns, as suggested by Brownlee et al.42
Conclusion
Our study confirms and expands on the findings of previ-
ous research to suggest profound sociodemographic and 
economic influences on insomnia prescribing patterns. 
Changing long-established physician prescribing patterns 
can be difficult, particularly if physicians have specific 
reasons for prescribing medications to specific populations. 
Future studies could explore intervention and educational 
strategies to ensure well informed clinical decisions 
that can withstand pharmaceutical marketing strategies 
and diagnostic uncertainties regarding the treatment of 
insomnia.
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